On Oct. 28, 2020, Eli Lilly announced the New England Journal of Medicine had published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company’s bamlanivimab (LY-CoV555) ﾖ a neutralizing antibody ﾖ in the COVID-19 outpatient setting.

This study focused on ambulatory COVID-19 patients being treated in the outpatient setting, whose symptoms did not require hospitalization at the time of enrollment.